-
公开(公告)号：MY136603A
公开(公告)日：2008-10-31
申请号：MYPI20012634
申请日：2001-06-05
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/02 , C12P21/08
Abstract: THERE IS DISCLOSED ANTIBODY MOLECULES CONTAINING AT LEAST ONE CDR DERIVED FROM A MOUSE MONOCLONAL ANTIBODY HAVING SPECIFICITY FOR HUMAN TNF . THERE IS ALSO DISCLOSED A CDR GRAFTED ANTIBODY WHEREIN AT LEAST ONE OF THE CDR'S IS A HYBRID CDR. FURTHER DISCLOSED ARE DNA SEQUENCES ENCODING THE CHAINS OF THE ANTIBODY MOLECULES, VECTORS, TRANSFORMED HOST CELLS AND USES OF THE ANTIBODY MOLECULES IN THE TREATMENT OF DISEASES MEDIATED BY TNF .
-
32.发明专利
公开(公告)号：NO20131316A
公开(公告)日：2002-04-08
申请号：NO20131316
申请日：2013-10-01
Applicant: UCB PHARMA SA
Inventor： KING DAVID JOHN , ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL
IPC: C07K16/24 , C12N15/09 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/02 , C12P21/08
CPC classification number: C07K16/241 , A61K47/6845 , A61K47/6875 , A61K2039/505 , C07K2317/24 , C07K2317/565
Abstract: Oppfinnelsen angår et antistoffmolekyl med spesifisitet for human TNFa, og angår også DNA sekvenser som koder for kjedene til antistoffmolekylet, vektorer, transformerte vertceller, fremgangsmåte for fremstilling av antistoffmolekylet, et terapeutisk/diagnostisk preparat samt anvendelser av antistoffmolekylet for behandling av sykdommer mediert ved TNFa.
-
33.发明专利
公开(公告)号：CY1121173T1
公开(公告)日：2020-05-29
申请号：CY191100095
申请日：2019-01-24
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/13 , A61K39/395 , A61K47/48 , A61K47/68 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C12N1/21 , C12P21/02 , C12P21/08
Abstract: Περιγράφονταιμόριααντισωμάτωνπουπεριέχουντουλάχιστονένα CDR προερχόμενοαπόμονοκλωνικάαντισώματαποντικού, μεειδικότηταπροςτονανθρώπινο TNFα. Περιγράφεταιεπίσηςένα CDR μοσχευμένοαντίσωμαόπουτουλάχιστονένααπότα CDR είναιέναυβριδικό CDR. Περιγράφονταιεπιπλέοναλληλουχίες DNA πουκωδικοποιούντιςαλυσίδεςτωναντισωμάτων, φορείς, μετασχηματισμένακύτταραξενιστέςκαιχρήσειςτωναντισωμάτωνγιατηνθεραπείανοσημάτωνπουδιαμεσολαβούνταιαπότον TNFα.
-
公开(公告)号：LU91674I9
公开(公告)日：2019-01-03
申请号：LU91674
申请日：2010-03-29
Applicant: UCB PHARMA SA
-
35.发明专利
公开(公告)号：LT2308975T
公开(公告)日：2016-11-10
申请号：LT10010795
申请日：2001-06-05
Applicant: UCB PHARMA SA
-
Patent Agency Ranking
公开(公告)号：CA2707766C
公开(公告)日：2013-05-21
申请号：CA2707766
申请日：2001-06-05
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/63 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/02 , C12P21/08
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF.alpha.. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF.alpha..
-
37.发明专利
公开(公告)号：ES2403217T3
公开(公告)日：2013-05-16
申请号：ES09176251
申请日：2001-06-05
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N15/09 , C12N15/13 , A61K39/395 , A61K47/48 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/24 , C07K16/46 , C07K19/00 , C12N1/21 , C12N15/62 , C12N15/70 , C12P21/02 , C12P21/08
Abstract: Una molécula de anticuerpo que tiene especificidad por el TNFα humano, caracterizada por que comprende a) una cadena pesada en la que el dominio variable comprende (i) una CDRH1 con la secuencia dada como SEC ID NO: 1 (H1 en la Figura 3), (ii) una CDRH2 como la secuencia dada como SEC ID NO: 2 (H2' en la Figura 3) o como SEC ID 5 NO: 7 (H2 en la Figura 3), y (iii) una CDRH3 con la secuencia dada como SEC ID NO: 3 (H3 en la figura 3), y b) una cadena ligera en la que el dominio variable comprende (i) una CDRL1 con la secuencia dada como SEC ID NO: 4 (L1 en la Figura 3), (ii) una CDRL2 como la secuencia dada como SEC ID NO: 5 (L2 en la Figura 3) y (iii) una CDRL3 con la secuencia dada como SEC ID NO: 6 (L3 en la figura 3), y .
-
38.发明专利
公开(公告)号：DK2230308T3
公开(公告)日：2013-05-06
申请号：DK09176251
申请日：2001-06-05
Applicant: UCB PHARMA SA
-
39.发明专利
公开(公告)号：PT2230308E
公开(公告)日：2013-05-03
申请号：PT09176251
申请日：2001-06-05
Applicant: UCB PHARMA SA
-
公开(公告)号：AU2013203712A1
公开(公告)日：2013-05-02
申请号：AU2013203712
申请日：2013-04-11
Applicant: BIOGEN MA INC , UCB PHARMA SA
Inventor： BURKLY LINDA , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE , TAYLOR FREDERICK R , HSU YEN-MING , SU LIHE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: Abstract This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD 154-CD40 interactions. FIGURE 19: inhibition of IgG Immune Response to Tetanus Toxoid in Cynomolgus Monkeys Primary Immune Response to TT -
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.033 seconds)
